Lista de obras - Niccolò Bartalucci - Dominio Público Uruguay

Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants

scientific article published on 22 July 2019

Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation.

artículo científico publicado en 2017

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value

artículo científico publicado en 2014

Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms

scientific article published on 22 May 2014

Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms

scientific article published on 12 November 2019

Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms

artículo científico publicado en 2013

Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis.

artículo científico

Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial

artículo científico publicado en 2015

Familial dominant epilepsy and mild pachygyria associated with a constitutional LIS1 mutation

scientific article published on 25 August 2018

Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis

artículo científico publicado en 2017

Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients

artículo científico publicado en 2017

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea

artículo científico publicado en 2018

Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data

artículo científico publicado en 2019

NanoR: A user-friendly R package to analyze and compare nanopore sequencing data

scientific article published on 09 May 2019

No role for CXCL12–G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia

scientific article published on 06 September 2007

Preclinical models for drug selection in myeloproliferative neoplasms.

artículo científico

Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.

artículo científico publicado en 2013

Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis

artículo científico publicado en 2018

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

artículo científico publicado en 2011

The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera

artículo científico publicado en 2009

mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms

artículo científico publicado en 2013

Lista de obras de Niccolò Bartalucci

Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants

Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation.

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value

Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms

Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms

Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms

Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis.

Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial

Familial dominant epilepsy and mild pachygyria associated with a constitutional LIS1 mutation

Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis

Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea

Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data

NanoR: A user-friendly R package to analyze and compare nanopore sequencing data

No role for CXCL12–G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia

Preclinical models for drug selection in myeloproliferative neoplasms.

Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.

Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera

mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms